Ramatroban (KAR101) as a potential treatment for silicosis
Targeting thromboxane/TP and prostaglandin D2/DP2 signaling with KAR101 may reduce lung inflammation, fibrosis and cardiopulmonary dysfunction in silicosis.
Ramatroban in the Silicosis mouse model
PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis
PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis
PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis
Multi-omics study of silicosis reveals the potential therapeutic targets PGD2 and TXA2
PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis
PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis
Pang and colleagues tested ramatroban in silicosis model constructed by a single intratracheal instillation of 8mg silica in 40µL PBS in male C57BL/6J mice of 8-10 weeks old. Pang et al, Theranostics, 2021, doi: 10.7150/thno.47627
PGD2 and TXA2 were significantly increased in silicosis mouse lungs
PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis
PGD2 and TXA2 were significantly increased in silicosis mouse lungs
Ramatroban reduces lung fibrosis induced by silica
Ramatroban reduces inflammation and improves pulmonary function
PGD2 and TXA2 were significantly increased in silicosis mouse lungs
Ramatroban reduces inflammation and improves pulmonary function
Ramatroban reduces inflammation and improves pulmonary function
Ramatroban reduces inflammation and improves pulmonary function
Ra=ramatroban; Crs=compliance of the respiratory system
Ramatroban improves cardiopulmonary function
Ramatroban reduces inflammation and improves pulmonary function
Ramatroban reduces inflammation and improves pulmonary function
RVSP=right ventricular systolic pressure; RVHI= right ventricular hypertrophy index